Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 itepekimab in chronic rhinosinusitis with nasal polyps
NL-OMON59364Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Itepekimab with Placebo (2 arms). Primary endpoints: Change from baseline in endoscopic nasal polyp score and Change from baseline in nasal congestion score. Started Sep 2025; status: active, not recruiting.
02
Drugs
itepekimab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NL-OMON59364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59364.